Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability